Table 1.
Clinical and laboratory data of the patient
| Date | 10/9/2013 | 6/24/2014 | 12/9/2014 | 12/31/2014 | 6/8/2015 | 8/19/2015 |
|---|---|---|---|---|---|---|
| Significant event | Initial diagnosis | MRD Positive | 1st
Relapse |
Persistent disease | Post-ASCTa | 2nd
Relapse |
| BM Blast (%) (0–5) | 61 | NA | 5 | 54 | 1 | 25 |
| WBC (x109/L) | 2.0 | 5.5 | 4.6 | 2.8 | 5.6 | 2.2 |
| PLT (x103/μL) | 88 | 383 | 202 | 79 | 133 | 79 |
| HB (g/dL) | 8.3 | 10.8 | 13.3 | 12.9 | 9.1 | 11.4 |
| Flow-cytometry analysis | Positiveb | Positive | Positivec | Positived | NA | Positive |
| G-Band karyotyping | NAe | NA | 46,XY | Complex | 46,XY | 46,XY |
| ETV6-RUNX1/iAMP21 FISH | Positive | Negative | Borderline Negative | Positive | NA | NA |
| ETV6-RUNX1 by PCR | NA | NA | NA | Positive | NA | NA |
| Treatment | CALGBf | Post- CALGB | Blinatumomab | Hyper-CVADg + Inotuzumab | 50 days Post-ASCT | EPOCHh + Rituxan |
a Post ASCT post allogeneic stem cell transplantation
bCD19lo, CD22+, cytoplasmic CD79a+, HLA-DR+, aberrant CD13 and CD33 expression, CD3-, CD10-, CD20-, surface Ig-, CD34-, CD38-,MPO-
cCD10+, CD13+, CD19lo, CD33+/lo, CD9-, CD20-, CD34-, surface Ig-
dCD10+, CD13+, CD19+, CD22+,CD33+ (subset), CD45 dim, CD38 dim, CD58, cytoplasmic CD79a, CD81, TdT+, cytoplasmic CD3-, CD15-, CD20-, CD25-, CD34-, CD66c-, CD117-, CRLF2-, cytoplasmic IgM-, MPO-
e NA not available
fCALGB: IT Cytarabine, Daunorubicin, Vincristine, IT Methotrexate, PEG Asparaginase and Prednisone
gHyper-CVAD: Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, Dexamethasone
hEPOCH: Etoposide, Vincristine, Cyclophosphamide, Doxorubicin Hydrochloride